PMC:7156805 / 46-356 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"8","span":{"begin":216,"end":225},"obj":"Disease"},{"id":"9","span":{"begin":280,"end":289},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"tao:has_database_id","subj":"8","obj":"MESH:D007239"},{"id":"A9","pred":"tao:has_database_id","subj":"9","obj":"MESH:D011565"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" use in dermatology\n\nTo the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the curr"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":216,"end":225},"obj":"Disease"},{"id":"T3","span":{"begin":280,"end":289},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005083"}],"text":" use in dermatology\n\nTo the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the curr"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":192,"end":193},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":" use in dermatology\n\nTo the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the curr"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":280,"end":289},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0003765"}],"text":" use in dermatology\n\nTo the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the curr"}

{"project":"LitCovid-sentences","denotations":[{"id":"T2","span":{"begin":21,"end":35},"obj":"Sentence"},{"id":"T3","span":{"begin":36,"end":170},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" use in dermatology\n\nTo the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the curr"}